Рекомендации ISPD, связанные с катетер-ассоциированными инфекциями 2023


DOI: https://dx.doi.org/10.18565/nephrology.2024.3.73-90

Kai Ming Chow, Philip Kam-Tao Li, Yeoungjee Cho, Ali Abu-Alfa, Sunita Bavanandan, Edwina A Brown, Brett Cullis, Dawn Edwards, Isabelle Ethier, Helen Hurst, Yasuhiko Ito, Thyago Proenc¸ a de Moraes, Johann Morelle, Naomi Runnegar, Anjali Saxena, Simon Wai-Yin So, Na Tian, David W Johnson.

1) Кафедра медицины и терапии, больница Принца Уэльского, Китайский университет Гонконга, Гонконг, Китай; 2) Исследовательский центр перитонеального диализа им. Кэрол и Ричарда Ю., факультет медицины и терапии, китайский университет Гонконга, Гонконг, Китай; 3) Австралийская сеть клинических исследований почки, университет Квинсленда, Брисбен, Австралия; 4) Отделение нефрологии, больница принцессы Александры, Брисбен, Австралия; 5) Отделение нефрологии и артериальной гипертензии больницы Американского университета, Бейрут, Ливан; 6) Отделение нефрологии Йельской школы медицины, Нью-Хейвен, Коннектикут, США; 7) Отделение нефрологии, больница Куала-Лумпур, Малайзия; 8) Центр почек и трансплантации Имперского колледжа, Imperial College NHS Trust, Лондон, Великобритания; 9) Отделение нефрологии и охраны здоровья детей Кейптаунского университета, ЮАР; 10) Национальный форум по ТХПН, Консультативный совет пациентов с почечной недостаточностью, США; 11) Отделение нефрологии, больница Монреальского университета, Монреаль, Канада; 12) Центр инноваций и оценки в области здравоохранения, исследовательский центр больницы Монреальского университета, Монреаль, Канада; 13) Школа здравоохранения и общества, университет Салфорд, Салфорд ройал, фонд Northern Care Alliance Trust, Великобритания; 14) Отделение нефрологии и ревматологии Медицинского университета Аити, Нагакуте, Япония; 15) Программа Pos-Graduacao em Ciencias dу Saude, Папский католический университет Параны, Куритиба, Бразилия; 16) Отделение нефрологии, университетская клиника Сен-Люк, Брюссель, Бельгия; 17) Инфекционная служба, больница принцессы Александры, университет Квинсленда, Брисбен, Австралия; 18) Медицинский факультет, отделение нефрологии, Стэнфордский университет, Калифорния, США; 19) Медицинский факультет, отделение нефрологии, медицинский центр долины Санта-Клара, Сан-Хосе, Калифорния, США; 20) Отделение фармации, больница Элис Хо Миулин Нетерсол, Тайпо, Гонконг; 21) Отделение нефрологии, больница общего профиля медицинского университета Нинся, Иньчуань, Китай
Катетер-ассоциированные инфекции являются важными факторами риска «потери» катетера и развития перитонита. В обновленных рекомендациях 2023 г. пересмотрены и уточнены определения и классификации инфекции места выхода катетера и туннельной инфекции. Новый целевой показатель общего уровня инфицирования места выхода катетера должен составлять не более 0,40 эпизода в год с учетом риска. Рекомендация по местному нанесению крема или мази с антибиотиком на место выхода катетера была понижена.
Новые рекомендации включают уточнения по поводу наложения повязки на место выхода и обновленную продолжительность лечения антибиотиками с акцентом на ранний клинический мониторинг для определения продолжительности терапии. Помимо удаления и повторной установки катетера предлагаются другие вмешательства с использованием катетера, включая снятие внешней манжеты или бритье, а также перемещение места выхода.
Ключевые слова: рекомендации ISPD, инфекция места выхода, результаты лечения, катетер-ассоциированные инфекции, антибиотикопрофилактика, антибактериальные средства, перитонеальный диализ, профилактика
Полный текст статьи доступен
в "Библиотеке Врача"

Литература


  1. Manera K.E., Johnson D.W., Craig J.C., et al. Establishing a core outcome set for peritoneal dialysis:

  2. report of the SONG-PD (Standardized Outcomes in Nephrology-Peritoneal Dialysis) consensus workshop. Am J Kidney Dis 2020; 75(3):404–412.

  3. Szeto C.C., Li P.K., Johnson D.W., et al. ISPD catheter-related infection recommendations: 2017 update. Perit Dial Int 2017; 37(2): 141–154.

  4. Li P.K., Chow K.M., Cho Y., et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 2022; 42(2):110–153.

  5. Atkins D., Best D., Briss P.A., et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490.

  6. Warady B.A., Bakkaloglu S., Newland J., et al. Consensus guidelines for the prevention and treatment of catheter related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int 2012; 32(Suppl 2):S32–S86.

  7. Gonthier D., Bernardini J., Holley J.L., et al. Erythema: Does it indicate infection in a peritoneal catheter exit site? Adv Perit Dial 1992;8:230–233.

  8. Rigo M., Pecoits-Filho R., Lambie M., et al. Clinical utility of a traditional score system for the evaluation of the peritoneal dialysis exit-site infection in a national multicentric cohort study. Perit Dial Int 2021;41(3):292–297.

  9. Schmitt R., Haller H. and Hiss M. Quiz page September 2012: erythematous rash around peritoneal dialysis catheter exit site. Am J Kidney Dis 2012;60(3):A29–A31.

  10. Schaefer F., Klaus G., Muller-Wiefel D.E., et al. Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS). J Am Soc Nephrol 1999;10(1):136–145.

  11. Twardowski ZJ and Prowant BF. Classification of normal and diseased exit sites. Perit Dial Int 1996;16(Suppl 3):S32–S50.

  12. Plum J., Sudkamp S and Grabensee B. Results of ultrasound assisted diagnosis of tunnel infections in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1994;23(1):99–104.

  13. van Diepen AT, Tomlinson GA and Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. Clin J Am Soc Nephrol 2012;7(8):1266–1271.

  14. Bernardini J., Bender F., Florio T. et al. Randomized, doubleblind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16(2):539–545.

  15. Crabtree J.H., Shrestha B.M., Chow K.M., et al. Creating and maintaining optimal peritoneal dialysis access in the adult patient: 2019 update. Perit Dial Int 2019;39(5):414–436.

  16. Kang S.H., Cho K.H., Kim A.Y., et al. Catheter salvage using revision for a peritoneal dialysis catheter with intractable exit site and/or tunnel infections. Semin Dial 2022;36(1):53–56.

  17. Nataatmadja M., Cho Y. and Johnson D.W. Continuous quality improvement initiatives to sustainably reduce peritoneal dialysis-related infections in Australia and New Zealand. Perit Dial Int 2016;36(5):472–477.

  18. Boudville N., Johnson D.W., Zhao J., et al. Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the peritoneal dialysis outcomes and practice patterns study. Nephrol Dial Transplant 2019;34(12):118–2126.

  19. Mushahar L., Mei L.W., Yusuf W.S., et al. Exit-site dressing and infection in peritoneal dialysis: a randomized controlled pilot trial. Perit Dial Int 2016;36(2):135–139.

  20. Lin J., Ye H., Li J., et al. Prevalence and risk factors of exit-site infection in incident peritoneal dialysis patients. Perit Dial Int 2020;40(2):164–170.

  21. Htay H., Johnson D.W., Wu S.Y., et al. Comparison of topical chlorhexidine and mupirocin for the prevention of exit-site infection in incident peritoneal dialysis patients. Perit Dial Int 2017;37(3):266–272.

  22. Committee H.T.W., Zhang L., Badve S.V., et al. Representativeness of honeypot trial participants to Australasian PD patients. Perit Dial Int 2017;37(5):516–522.

  23. Johnson D.W., Badve S.V., Pascoe E.M., et al. Antibacterial honey for the prevention of peritonealdialysis-related infections (HONEYPOT): a randomised trial. Lancet Infect Dis 2014;14(1):23–30.

  24. Chen S.S., Sheth H., Piraino B. et al. Long-term exit-site gentamicin prophylaxis and gentamicin resistance in a peritoneal dialysis program. Perit Dial Int 2016;36(4):387–389.

  25. Ferreira A.C., Fernandes V., Rodrigues A., et al. Peritoneal dialysis exit-site care protocols in Portugal and its association with catheter-related infections. Blood Purif 2023;52:1–7.

  26. Campbell D., Mudge D.W., Craig J.C., et al. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database Syst Rev 2017;4:CD004679.

  27. Gadallah M.F., Ramdeen G., Torres C., et al. Preoperative vancomycin prophylaxis for newly placed peritoneal dialysis catheters prevents postoperative peritonitis. Adv Perit Dial 2000;16:199–203.

  28. Grothe C., Taminato M., Belasco A., et al. Prophylactic treatment of chronic renal disease in patients undergoing peritoneal dialysis and colonized by Staphylococcus aureus: a systematic review and meta-analysis. BMC Nephrol 2016;17(1):115.

  29. Htay H., Johnson D.W., Craig J.C., et al. Catheter type, placement and insertion techniques for preventing catheter-related infections in chronic peritoneal dialysis patients. Cochrane Database Syst Rev 2019;5:CD004680.

  30. Agarwal A., Whitlock R.H., Bamforth R.J., et al. Percutaneous versus surgical insertion of peritoneal dialysis catheters: a systematic review and meta-analysis. Can J Kidney Health Dis 2021;8:20543581211052731.

  31. Dombros N., Dratwa M., Feriani M., et al. European best practice guidelines for peritoneal dialysis. 3 Peritoneal access. Nephrol Dial Transplant 2005;20(Suppl 9):ix8–ix12.

  32. Prowant B.F. and Twardowski Z.J. Recommendations for exit care. Perit Dial Int 1996;16(Suppl 3):S94–S99.

  33. Htay H., Johnson D.W., Craig J.C., et al. Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease. Cochrane Database Syst Rev 2020;12:CD012913.

  34. Nessim S.J., Bargman J.M. and Jassal S.V. Relationship between double-cuff versus single-cuff peritoneal dialysis catheters and risk of peritonitis. Nephrol Dial Transplant 2010;25(7):2310–2314.

  35. Eklund B., Honkanen E., Kyllonen L., et al. Peritoneal dialysis access: prospective randomized comparison of single-cuff and double-cuff straight Tenckhoff catheters. Nephrol Dial Transplant 1997;12(12):2664–2666.

  36. Crabtree J.H., Burchette R.J., Siddiqi R.A., et al. The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections. Perit Dial Int 2003;23(4):368–374.

  37. Kim C.Y., Kumar A., Sampath L. et al. Evaluation of an antimicrobial-impregnated continuous ambulatory peritoneal dialysis catheter for infection control in rats. Am J Kidney Dis 2002;39(1):165–173.

  38. Figueiredo AE, Bernardini J, Bowes E, et al. A syllabus for teaching peritoneal dialysis to patients and caregivers. Perit Dial Int 2016;36(6):592–605.

  39. Zhang L., Hawley C.M., Johnson D.W. Focus on peritoneal dialysis training: working to decrease peritonitis rates. Nephrol Dial Transplant 2016;31(2):214–222.

  40. Cheetham M.S. Zhao J., McCullough K., et al. International peritoneal dialysis training practices and the risk of peritonitis. Nephrol Dial Transplant 2022;37(5):937–949.

  41. Dryden M.S., Ludlam H.A., Wing A.J., et al. Active intervention dramatically reduces CAPDassociated infection. Adv Perit Dial 1991;7:125–128.

  42. Hall G., Bogan A., Dreis S., et al. New directions in peritoneal dialysis patient training. Nephrol Nurs J 2004;31(2):149–154. 159–163.

  43. Chow J.S., Adams K., Cho Y., et al. Targeted Education ApproaCH to improve Peritoneal Dialysis Outcomes (TEACH-PD): a feasibility study. Perit Dial Int 2020;40(2):153–163.

  44. Gokal R., Ash S.R., Helfrich G.B., et al. Peritoneal catheters and exit-site practices: toward optimum peritoneal access. Perit Dial Int 1993; 13(1):29–39.

  45. Chang J.H., Oh J., Park S.K., et al. Frequent patient retraining at home reduces the risks of peritoneal dialysis-related infections: a randomised study. Sci Rep 2018;8(1):12919.

  46. Strippoli G.F., Tong A., Johnson D., et al. Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. Am J Kidney Dis 2004;44(4):591–603.

  47. Tacconelli E., Carmeli Y., Aizer A. et al. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis 2003;37(12):1629–1638.

  48. Bernardini J., Piraino B., Holley J., et al. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996;27(5):695–700.

  49. Xu G., Tu W. and Xu C. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2010;25(2):587–592.

  50. Perez-Fontan M., Rosales M., Rodriguez-Carmona A., et al. Mupirocin resistance after long-term use for staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002;39(2):337–341.

  51. Piraino B. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Was it effective? Nephrol Dial Transplant 2010;25(2):349–352.

  52. Obata Y., Murashima M., Toda N., et al. Topical application of mupirocin to exit sites in patients on peritoneal dialysis: a systematic review and meta-analysis of randomized controlled trials. Ren Replace Ther 2020;6:12.

  53. Nochaiwong S., Ruengorn C., Noppakun K., et al. Comparative Effectiveness of Local Application of Chlorhexidine Chow et al. 15 Gluconate, Mupirocin Ointment, and Normal Saline for the Prevention of Peritoneal Dialysis-related Infections (COSMO-PD Trial): a multicenter randomized, doubleblind, controlled protocol. Trials 2019;20(1):754.

  54. Nessim SJ and Jassal SV. Gentamicin-resistant infections in peritoneal dialysis patients using topical gentamicin exit-site prophylaxis: a report of two cases. Perit Dial Int 2012;32(3):339–341.

  55. Pierce D.A., Williamson J.C., Mauck V.S., et al. The effect on peritoneal dialysis pathogens of changing topical antibiotic prophylaxis. Perit Dial Int 2012; 32(5): 525–530.

  56. Lo M.W, Mak SK, Wong YY, et al. Atypical mycobacterial exit-site infection and peritonitis in peritoneal dialysis patients on prophylactic exit-site gentamicin cream. Perit Dial Int 2013; 33(3):267–272.

  57. Wong P.N., Tong G.M., Wong Y.Y., et al. Alternating mupirocin/gentamicin is associated with increased risk of fungal peritonitis as compared with gentamicin alone – results of a randomized open-label controlled trial. Perit Dial Int 2016;36(3):340–346.

  58. Zhang L., Badve S.V., Pascoe E.M., et al. The effect of exit-site antibacterial honey versus nasal mupirocin prophylaxis on the microbiology and outcomes of peritoneal dialysis-associated peritonitis and exit-site infections: a sub-study of the honeypot trial. Perit Dial Int 2015;35(7):712–721.

  59. McQuillan R.F., Chiu E., Nessim S., et al. A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study. Clin J Am Soc Nephrol 2012;7(2):297–303.

  60. Nunez-Moral M., Sanchez-Alvarez E., Gonzalez-Diaz I., et al. Exit-site infection of peritoneal catheter is reduced by the use of polyhexanide. Results of a prospective randomized trial. Perit Dial Int 2014;34(3):271–277.

  61. Findlay A., Serrano C., Punzalan S., et al. Increased peritoneal dialysis exit site infections using topical antiseptic polyhexamethylene biguanide compared to mupirocin: results of a safety interim analysis of an open-label prospective randomized study. Antimicrob Agents Chemother 2013;57(5):2026–2028.

  62. Tam B.M. and Chow S.K. A preliminary report on the effectiveness of nanotechnology antimicrobial spray dressing in preventing Tenckhoff catheter exit-site infection. Perit Dial Int 2014;34(6):670–673.

  63. Khandelwal M., Bailey S., Izatt S., et al. Structural changes in silicon rubber peritoneal dialysis catheters in patients using mupirocin at the exit site. Int J Artif Organs 2003;26(10):913–917.

  64. Gardezi A.I., Schlageter K.W., Foster D.M., et al. Erosion of the silicone peritoneal dialysis catheter with the use of gentamicin cream at the exit site. Adv Perit Dial 2016;32:15–18.

  65. Riu S., Ruiz C.G., Martinez-Vea A., et al. Spontaneous rupture of polyurethane peritoneal catheter. A possible deleterious effect of mupirocin ointment. Nephrol Dial Transplant 1998;13(7):1870–1871.

  66. Luzar MA, Brown CB, Balf D, et al. Exit-site care and exit site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial. Perit Dial Int 1990; 10(1): 25–29.

  67. Wilson A.P., Lewis C., O’Sullivan H., et al. The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD). J Hosp Infect 1997;35(4):287–293.

  68. Berns J.S. and Tokars JI. Preventing bacterial infections and antimicrobial resistance in dialysis patients. Am J Kidney Dis 2002;40(5):886–898.

  69. Htay H., Choo J.C.J., Johnson D.W., et al. Chlorhexidine impregnated sponge dressing for prevention of catheter exit-site infection in peritoneal dialysis patients: a pilot study. Int Urol Nephrol 2021;53(4):803–812.

  70. Mendoza-Guevara , Castro-Vazquez , Aguilar-Kitsu , et al. Amuchina 10% solution, safe antiseptic for preventing infections of exit-site of Tenckhoff catheters, in the pediatric population of a dialysis program. Contrib Nephrol 2007;154:139–144.

  71. Chua A.N., Goldstein S.L., Bell D., et al. Topical mupirocin/ sodium hypochlorite reduces peritonitis and exit-site infection rates in children. Clin J Am Soc Nephrol 2009;4(12):1939–1943.

  72. Jones LL, Tweedy L and Warady BA. The impact of exit-site care and catheter design on the incidence of catheter-related infections. Adv Perit Dial 1995;11:302–305.

  73. Shelton D.M. A comparison of the effects of two antiseptic agents on Staphylococcus epidermidis colony forming units at the peritoneal dialysis catheter exit site. Adv Perit Dial 1991;7:120–124.

  74. Ceri M., Yilmaz S.R., Unverdi S., et al. Effect of local polyhexanide application in preventing exitsite infection and peritonitis: a randomized controlled trial. Ther Apher Dial 2020; 24(1): 81–84.

  75. Wong SCY, Wong SC, Chen JHK, et al. Polyclonal Burkholderia cepacia complex outbreak in peritoneal dialysis patients caused by contaminated aqueous chlorhexidine. Emerg Infect Dis 2020; 26(9): 1987–1997.

  76. Romero-Gomez MP, Quiles-Melero MI, Pena Garcia P, et al. Outbreak of Burkholderia cepacia bacteremia caused by contaminated chlorhexidine in a hemodialysis unit. Infect Control Hosp Epidemiol 2008; 29(4): 377–378.

  77. Kaitwatcharachai C, Silpapojakul K, Jitsurong S, et al. An outbreak of Burkholderia cepacia bacteremia in hemodialysis patients: an epidemiologic and molecular study. Am J Kidney Dis 2000; 36(1): 199–204.

  78. Gleeson S, Mulroy E, Bryce E, et al. Burkholderia cepacia: an outbreak in the peritoneal dialysis unit. Perit Dial Int 2019; 39(1): 92–95.

  79. Ding XR, Huang HE, Liao YM, et al. Daily self-care practices influence exit-site condition in patients having peritoneal dialysis: a multicenter cross-sectional survey. J Adv Nurs 2021; 77(5): 2293–2306.

  80. Bennett PN, Bohm C, Harasemiw O, et al. Physical activity and exercise in peritoneal dialysis: International Society for Peritoneal Dialysis and the global renal exercise network practice recommendations. Perit Dial Int 2022;42(1): 8–24.

  81. Soetendorp H, Kliuk-Ben Bassat O, Wasserman A, et al. Water avoidance and modification of exit-site care with stoma bag results in reduced exit-site infection rate in peritoneal dialysis patients. Clin Nephrol 2021; 95(6):323–331.

  82. Taheri S, Ahmadnia M, Mortazavi M, et al. Comparing the effect of dressing versus no-dressing on exit site infection and peritonitis in chronic ambulatory peritoneal dialysis patients. Adv Biomed Res 2017; 6: 5.

  83. Figueiredo AE, de Mattos C, Saraiva C, et al. Comparison between types of dressing following catheter insertion and early exit-site infection in peritoneal dialysis. J Clin Nurs 2017; 26(21–22): 3658–3663.

  84. Vychytil A, Lilaj T, Lorenz M, et al. Ultrasonography of the catheter tunnel in peritoneal dialysis patients: What are the indications? Am J Kidney Dis 1999; 33(4): 722–727.

  85. Korzets Z, Erdberg A, Golan E, et al. Frequent involvement of the internal cuff segment in CAPD peritonitis and exit site infection – an ultrasound study. Nephrol Dial Transplant 1996; 11(2): 336– 339.

  86. Kwan TH, Tong MK, Siu YP, et al. Ultrasonography in the management of exit site infections in peritoneal dialysis patients. Nephrology (Carlton) 2004; 9(6): 348–352.

  87. Granata A, Rahbari E, Di Nicolo P, et al. The underrated role of ultrasound in peritoneal dialysis. J Ultrasound Med 2022; 41(2): 301–310.

  88. Granata A, Rahbari E, Pesce F, et al. Contrast-enhanced ultrasound in peritoneal dialysis: when and how to perform it. J Nephrol 2022; 35(5): 1329–1337.

  89. Hui YH, So WK, Ng MS, et al. Treating peritoneal dialysis catheter exit-site granulomas with chlorhexidine swabstick: a pilot study. J Ren Care 2021; 47(2): 103–112.

  90. Matinfar M, Taheri S, Karimi S, et al. Successful treatment of peritoneal dialysis catheter exit-site granuloma with silver ion-based dressing. J Vasc Access 2021; 22(4): 685–686.

  91. Winthrop KL, Ku JH, Marras TK, et al. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J 2015; 45(4): 1177–1179.

  92. Au CWH, Yap DYH, Chan JFW, et al. Exit site infection and peritonitis due to Serratia species in patients receiving peritoneal dialysis: epidemiology and clinical outcomes. Nephrology (Carlton) 2021; 26(3): 255–261.

  93. Yap DY, Choy CB, Mok MM, et al. Burkholderia cepacia – an uncommon cause of exit-site infection in a peritoneal dialysis patient. Perit Dial Int 2014; 34(4): 471–472.

  94. Lew SQ, Wallace EL, Srivatana V, et al. Telehealth for home dialysis in COVID-19 and beyond: a perspective from the American society of nephrology COVID-19 home dialysis subcommittee. Am J Kidney Dis 2021; 77(1): 142–148.

  95. Montravers P, Snauwaert A and Welsch C. Current guidelines and recommendations for the management of skin and soft tissue infections. Curr Opin Infect Dis 2016; 29(2): 131–138.

  96. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59(2): 147–159.

  97. Auricchio S, Giovenzana ME, Pozzi M, et al. Fungal peritonitis in peritoneal dialysis: a 34-year single centre evaluation. Clin Kidney J 2018; 11(6): 874–880.

  98. Li R, Zhang D, He J, et al. Characteristics analysis, clinical outcome and risk factors for fungal peritonitis in peritoneal dialysis patients: a 10-year case-control study. Front Med (Lausanne) 2021; 8: 774946.

  99. Lo CY, Chu WL, Wan KM, et al. Pseudomonas exit-site infections in CAPD patients: evolution and outcome of treatment. Perit Dial Int 1998; 18(6): 637–640.

  100. Kazmi HR, Raffone FD, Kliger AS, et al. Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1992; 2(10): 1498–1501.

  101. Burkhalter F, Clemenger M, Haddoub SS, et al. Pseudomonas exit-site infection: treatment outcomes with topical gentamicin in addition to systemic antibiotics. Clin Kidney J 2015; 8(6): 781–784.

  102. Szeto CC, Chow KM, Kwan BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases. Clin J Am Soc Nephrol 2007; 2(2): 245–251.

  103. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52(3): 285–292.

  104. Bnaya A, Wiener-Well Y, Soetendorp H, et al. Nontuberculous mycobacteria infections of peritoneal dialysis patients: a multicenter study. Perit Dial Int 2021; 41(3): 284–291.

  105. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175(4): 367–416.

  106. Chamarthi G, Modi D, Andreoni K, et al. Simultaneous catheter removal and reinsertion, is it acceptable in M. abscessus exit site infection? CEN Case Rep 2021; 10(4): 483–489.

  107. Vychytil A, Lorenz M, Schneider B, et al. New criteria for management of catheter infections in peritoneal dialysis patients using ultrasonography. J Am Soc Nephrol 1998; 9(2): 290–296.

  108. Beckwith H, Clemenger M, McGrory J, et al. Repeat peritoneal dialysis exit-site infection:definition and outcomes. Perit Dial Int 2019; 39(4): 344–349.

  109. Nadarajah L, Yaqoob MM and Fan S. Persistent colonization of exit site is associated with modality failure in peritoneal dialysis. Perit Dial Int 2022; 42(1): 96–99.

  110. Szeto CC, Chow KM, Wong TY, et al. Feasibility of resuming peritoneal dialysis after severe peritonitis and Tenckhoff catheter removal. J Am Soc Nephrol 2002; 13(4): 1040–1045.

  111. Lui SL, Yip T, Tse KC, et al. Treatment of refractory Pseudomonas aeruginosa exit-site infection by simultaneous removal and reinsertion of peritoneal dialysis catheter. Perit Dial Int 2005; 25(6): 560–563. Chow et al. 17.

  112. Posthuma N, Borgstein PJ, Eijsbouts Q, et al. Simultaneous peritoneal dialysis catheter insertion and removal in catheter-related infections without interruption of peritoneal dialysis. Nephrol Dial Transplant 1998; 13(3): 700–703.

  113. Crabtree JH and Siddiqi RA. Simultaneous catheter replacement for infectious and mechanical complications without interruption of peritoneal dialysis. Perit Dial Int 2016; 36(2): 182–187.

  114. Paterson AD, Bishop MC, Morgan AG, et al. Removal and replacement of Tenckhoff catheter at a single operation: successful treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis. Lancet 1986; 2(8518): 1245–1247.

  115. Swartz R, Messana J, Reynolds J, et al. Simultaneous catheter replacement and removal in refractory peritoneal dialysis infections. Kidney Int 1991; 40(6): 1160–1165.

  116. Scalamogna A, Nardelli L, Zubidat D, et al. Simultaneous replacement and removal of the peritoneal catheter is effective in patients with refractory tunnel infections sustained by S. aureus. Int Urol Nephrol 2023; 55(1): 151–155.

  117. Washida N and Itoh H. The role of non-tuberculous mycobacteria in peritoneal dialysis-related infections: a literature review. Contrib Nephrol 2018; 196: 155–161.

  118. Yoshimura R, Kawanishi M, Fujii S, et al. Peritoneal dialysis-associated infection caused by Mycobacterium abscessus: a case report. BMC Nephrol 2018; 19(1): 341.

  119. Scalamogna A, Nardelli L and Castellano G. The use of mini-invasive surgical techniques to treat refractory exit site and tunnel infections in peritoneal dialysis patients: a clinical approach. J Nephrol. Epub ahead of print 15 Dec 2022. DOI: 10.1007/s40620-022-01479-7.

  120. Taber TE, Hegeman TF, York SM, et al. Treatment of pseudomonas infections in peritoneal dialysis patients. Perit Dial Int 1991; 11(3): 213–216.

  121. Meng C, Beco A, Oliveira A, et al. Peritoneal dialysis cuff shaving – a salvage therapy for refractory exit-site infections. Perit Dial Int 2019; 39(3): 276–281.

  122. Scalamogna A, De Vecchi A, Maccario M, et al. Cuff shaving procedure. A rescue treatment for exit-site infection unresponsive to medical therapy. Nephrol Dial Transplant 1995; 10(12): 2325– 2327.

  123. Debowski JA, Waerp C, Kjellevold SA, et al. Cuff extrusion in peritoneal dialysis: single-centre experience with the cuff-shaving procedure in five patients over a 4-year period. Clin Kidney J 2017; 10(1): 131–134.

  124. Tan SY and Thiruventhiran T. Catheter cuff shaving using a novel technique: a rescue treatment for persistent exit-site infections. Perit Dial Int 2000; 20(4): 471–472.

  125. Kirmizis D, Bowes E, Ansari B, et al. Exit-site relocation: a novel, straightforward technique for exit-site infections. Perit Dial Int 2019; 39(4): 350–355.

  126. Cho KH, Do JY, Park JW, et al. Catheter revision for the treatment of intractable exit site infection/tunnel infection in peritoneal dialysis patients: a single centre experience. Nephrology (Carlton) 2012; 17(8):760–766.

  127. Clouatre Y, Cartier P, Charbonneau R, et al. Outpatient CAPD catheter salvage for persistent exitsite/tunnel infection. Nephrol Dial Transplant 2000; 15(2): 231–234.

  128. Oki R, Hamasaki Y, Komaru Y, et al. Catheter diversion procedure with exit-site renewal promotes peritoneal dialysis catheter survival. Kidney Int Rep 2021; 6(2): 325–332.

  129. Nichols WK and Nolph KD. A technique for managing exit site and cuff infection in Tenckhoff catheters. Perit Dial Int 1983; 3(4): 4–5.

  130. Muraoka K, Ishibashi Y, Yamaguchi J, et al. Early partial re-implantation of Tenckhoff catheters to treat intractable exit-site or tunnel infection. Perit Dial Int 2011; 31(3): 350–353.

  131. Soon JJY, Ng NZP, Lee SQ, et al. Are salvage techniques safe and effective in the treatment of peritoneal dialysis catheter-related exit-site and tunnel infections? A systematic review and description of the authors’ preferred technique. Perit Dial Int 2022; 42(6): 591–601.

  132. Cancarini GC, Manili L, Brunori G, et al. Simultaneous catheter replacement-removal during infectious complications in peritoneal dialysis. Adv Perit Dial 1994; 10: 210–213.

  133. Cheung AH, Wheeler MS, Limm WM, et al. A salvage technique for continuous ambulatory peritoneal dialysis catheters with exit-site infections. Am J Surg 1995; 170(1): 60–61.

  134. Wu YM, Tsai MK, Chao SH, et al. Surgical management of refractory exit-site/tunnel infection of Tenckhoff catheter: technical innovations of partial replantation. Perit Dial Int 1999; 19(5): 451– 454.

  135. Fukasawa M, Matsushita K, Tanabe N, et al. A novel salvage technique that does not require catheter removal for exit-site infection. Perit Dial Int 2002; 22(5): 618–621.

  136. Yang PJ, Lee CY, Yeh CC, et al. Mini-laparotomy implantation of peritoneal dialysis catheters: outcome and rescue. Perit Dial Int 2010; 30(5): 513–518.

  137. Macchini F, Testa S, Valade A, et al. Conservative surgical management of catheter infections in children on peritoneal dialysis. Pediatr Surg Int 2009; 25(8): 703–707.

  138. Crabtree JH and Burchette RJ. Surgical salvage of peritoneal dialysis catheters from chronic exitsite and tunnel infections. Am J Surg 2005; 190(1): 4–8.

  139. Terawaki H, Nakano H, Ogura M, et al. Unroofing surgery with en bloc resection of the skin and tissues around the peripheral cuff. Perit Dial Int 2013; 33(5): 573–576.

  140. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol 1999; 20(4): 250–278. quiz 279–280.

  141. Schroder CH, Severijnen RS, de Jong MC, et al. Chronic tunnel infections in children: removal and replacement of the continuous ambulatory peritoneal dialysis catheter in a single operation. Perit Dial Int 1993; 13(3): 198–200.

  142. Goldraich I, Mariano M, Rosito N, et al. One-step peritoneal catheter replacement in children. Adv Perit Dial 1993; 9: 325–328. 18 Peritoneal Dialysis International XX(X)

  143. Bernard L, Arvieux C, Brunschweiler B, et al. Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. N Engl J Med 2021; 384(21): 1991–2001.

  144. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short course antimicrobial therapy for intraabdominal infection. N Engl J Med 2015; 372(21): 1996–2005.

  145. Leung DKC, Mok WFM, Yu DMW, et al. Use of distilled white vinegar dressing supplemental to oral antibiotics in the management of Pseudomonas aeruginosa exit site infection in continuous ambulatory peritoneal dialysis patients. Hong Kong J Nephrol 2001; 3(1): 38–40.

  146. Carson CF, Ash O and Chakera A. In vitro data support the investigation of vinegar as an antimicrobial agent for PD-associated Pseudomonas exit site infections. Nephrology (Carlton) 2017; 22(2): 179–181.


Похожие статьи

К содержанию номера

Бионика Медиа